Copyright
©The Author(s) 2023.
World J Virol. Dec 25, 2023; 12(5): 296-308
Published online Dec 25, 2023. doi: 10.5501/wjv.v12.i5.296
Published online Dec 25, 2023. doi: 10.5501/wjv.v12.i5.296
Factors | ALL | High HBV DNA | Low HBV DNA | P value |
Case n = 1603 | Case n = 815 | Case n = 788 | ||
Demographic | ||||
Age (yr) | 52 (43–60) | 51 (40–60) | 53 (45–61) | 0.010 |
Male gender | 1015 (63.28) | 131 (69.6) | 401 (68.2) | 0.703 |
Laboratory tests | ||||
FBG (mmol/L) | 5.10 (4.61–5.87) | 5.00 (4.5–5.7) | 5.21 (4.77–6.00) | < 0.001 |
ALT (U/L) | 47.95 (25.00–109.92) | 68.3 (37.1–155.83) | 31.7 (20.3–67.7) | < 0.001 |
AST (U/L) | 41.19 (25.00–81.97) | 52.95 (33.33–106.8) | 29.86 (21.31–55.55) | < 0.001 |
ALP (U/L) | 81.40 (63.63–109.00) | 85.30 (66.00–116.60) | 76.65 (61.9–104.00) | 0.003 |
γ-GGT (U/L) | 51.20 (22.89–113.36) | 60.00 (29.13–135.00) | 41.60 (18.97–100.12) | 0.038 |
LDH (U/L) | 194.8 (170.23–231.10) | 196.00 (171.56–239.00) | 194.00 (168.94–224.61) | 0.006 |
Albumin (g/L) | 40.70 (35.33–44.70) | 39.60 (33.02–43.51) | 41.96 (37.49–45.80) | 0.045 |
Total bilirubin (µmol/L) | 16.53 (11.63–25.24) | 17.60 (12.20–27.70) | 15.39 (11.37–23.20) | 0.165 |
Bile acids (µg/mL) | 11.00 (5.18–30.00) | 14.30 (6.30–34.20) | 8.70 (4.26–23.88) | 0.002 |
Total cholesterol (mmol/L) | 4.25 (3.55–5.01) | 4.19 (3.50–4.92) | 4.37 (3.61–5.10) | 0.517 |
Triglycerides (mmol/L) | 1.06 (0.73–1.53) | 1.02 (0.73–1.44) | 1.12 (0.74–1.71) | < 0.001 |
HDL-C (mmol/L) | 1.15 (0.90–1.41) | 1.19 (0.91–1.43) | 1.12 (0.89–1.38) | 0.029 |
LDL-C (mmol/L) | 2.40 (1.87–2.98) | 2.27 (1.76–2.89) | 2.51 (1.95–3.10) | 0.018 |
apoA (g/L) | 1.19 (1.01–1.38) | 1.14 (0.99–1.27) | 1.18 (1.02–1.39) | 0.849 |
apoB (g/L) | 0.87 (0.70–1.06) | 0.84 (0.69–1.01) | 0.91 (0.73–1.10) | 0.002 |
Steatosis | 163 (10.2) | 25 (3.1) | 138 (17.5) | < 0.001 |
HBeAg sero-positive | 661 (41.2) | 460(56.4) | 201 (25.5) | < 0.001 |
Factors | HBeAg sero-positive | HBeAg sero-negative | ||||
High HBV DNA | Low HBV DNA | P value | High HBV DNA | Low HBV DNA | P value | |
Case n = 460 | Case n = 201 | Case n = 355 | Case n = 587 | |||
Demographic | ||||||
Age (yr) | 45 (36–59) | 50 (40–59) | 0.106 | 54 (45–61) | 55 (46–61) | 0.564 |
Male gender | 314 (68.2) | 137 (68.1) | 0.412 | 128 (56.6) | 93 (68.4) | 0.026 |
Laboratory tests | ||||||
FBG (mmol/L) | 4.83 (4.40–5.35) | 5.10 (4.60–5.90) | < 0.001 | 5.23 (4.73–6.20) | 5.28 (4.80–6.06) | 0.795 |
ALT (U/L) | 83.21 (43.45–190.62) | 51.60 (26.62–120.07) | < 0.001 | 53.00 (3200–127.00) | 27.60 (19.38–53.60) | < 0.001 |
AST (U/L) | 59.30 (38.01–130.1) | 46.85 (26.00–93.18) | < 0.001 | 46.50 (37.57–116.55) | 27.00 (20.72–46.47) | < 0.001 |
ALP (U/L) | 87.50 (67.98–117.09) | 90.18 (67.00–127.15) | 0.489 | 83.40 (65.20–111.90) | 74.00 (60.00–96.00) | < 0.001 |
γ-GGT (U/L) | 64.61 (33.50–139.92) | 68.25 (33.25–145.87) | 0.615 | 52.00 (21.90–115.69) | 69.6 (33.40–164.30) | < 0.001 |
LDH (U/L) | 195.00 (171.92–238.32) | 193.40 (167.37–228.97) | 0.38 | 197.00 (170.08–239.14) | 194.00 (169.00–222.39) | 0.077 |
Albumin (g/L) | 39.40 (32.81–43.36) | 40.30 (34.89–44.50) | 0.026 | 54.00 (45.00–61.50) | 43.90 (38.00–47.70) | < 0.001 |
Total bilirubin (µmol/L) | 17.90 (12.40–28.35) | 17.80 (13.21–32.52) | 0.751 | 17.20 (11.9–27.00) | 14.71 (11.08–22.47) | < 0.001 |
Bile acids (ug/mL) | 16.60 (8.01—38.77) | 16.50 (8.01–41.52) | 0.904 | 10.06 (4.98–27.50) | 7.07 (3.73–16.54) | < 0.001 |
Total cholesterol (mmol/L) | 4.16 (3.50–4.85) | 4.00 (3.30–4.83) | 0.674 | 4.22 (3.49–5.01) | 4.46 (3.71–5.15) | 0.019 |
Triglycerides (mmol/L) | 1.03 (0.73–1.44) | 1.08 (0.71–1.71) | 0.429 | 1.04 (0.73–1.41) | 1.14 (0.75–1.72) | 0.002 |
HDL-C (mmol/L) | 1.19 (0.90–1.43) | 1.08 (0.81–1.40) | 0.041 | 1.20 (0.92–1.44) | 1.12 (0.91–1.38) | 0.13 |
LDL-C (mmol/L) | 2.25 (1.76–2.90) | 2.41 (1.89–3.06) | 0.041 | 2.31 (1.72–2.87) | 2.54 (1.97–3.12) | < 0.001 |
apoA (g/L) | 1.17 (0.97–1.35) | 1.15 (0.92–1.30) | 0.204 | 1.21 (1.00–1.40) | 1.20 (1.04–1.41) | 0.624 |
apoB (g/L) | 0.85 (0.69–1.02) | 0.91 (0.70–1.12) | 0.01 | 0.83 (0.68–1.00) | 0.91 (0.74–1.09) | < 0.001 |
Steatosis | 11 (2.4) | 37 (18.4) | < 0.001 | 11 (3.0%) | 101 (17.2) | < 0.001 |
P value | OR (95%CI) | |
HBsAg sero-positive | ||
Steatosis | < 0.001 | 0.15 (0.10–0.23) |
Triglyceride | 0.027 | 0.83 (0.70–0.98) |
apoA | 0.009 | 0.47 (0.26–0.83) |
apoB | 0.905 | 0.99 (0.91–1.08) |
Cholesterol | 0.009 | 1.39 (1.09–1.77) |
HDL-C | 0.171 | 1.38 (0.87–2.18) |
LDL-C | < 0.001 | 0.59 (0.45–0.77) |
HBeAg sero-positive | ||
Steatosis | < 0.001 | 0.11 (0.05–0.22) |
Triglyceride | 0.077 | 0.74 (0.53–1.03) |
apoA | 0.846 | 1.10 (0.41–2.96) |
apoB | 0.5 | 0.69 (0.23–2.02) |
Cholesterol | < 0.001 | 2.33 (1.55–3.51) |
HDL-C | 0.204 | 0.61 (0.29–1.30) |
LDL-C | < 0.001 | 0.38 (0.24–0.60) |
HBeAg sero-negative | ||
Steatosis | < 0.001 | 0.19 (0.11–0.35) |
Triglyceride | 0.002 | 0.69 (0.55–0.87) |
apoA | 0.209 | 0.62 (0.29–1.31) |
apoB | 0.713 | 1.02 (0.91–1.14) |
Cholesterol | 0.004 | 1.69 (1.19–2.40) |
HDL-C | 0.904 | 0.96 (0.51–1.81) |
LDL-C | < 0.001 | 0.46 (0.31–0.67) |
- Citation: Wang C, Gao XY, Han M, Jiang MC, Shi XY, Pu CW, Du X. Perilipin2 inhibits the replication of hepatitis B virus deoxyribonucleic acid by regulating autophagy under high-fat conditions. World J Virol 2023; 12(5): 296-308
- URL: https://www.wjgnet.com/2220-3249/full/v12/i5/296.htm
- DOI: https://dx.doi.org/10.5501/wjv.v12.i5.296